Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 30 of 33 results for ibrutinib

  1. Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)

    Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    27 February 2019
    View recommendations

    Sections for TA561

  2. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)

    Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab for untreated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    9 December 2020
    View recommendations

    Sections for TA663

  3. Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)

    Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.

    Technology appraisal guidance
    Published
    19 October 2022
    View recommendations

    Sections for TA833

  4. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma (TA677)

    Evidence-based recommendations on brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton’s tyrosine kinase (BTK) inhibitor.

    Technology appraisal guidance
    Published
    24 February 2021
    View recommendations

    Sections for TA677

  5. Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]

    In development Reference number: GID-TA11298 Expected publication date:  29 January 2026

    Technology appraisal guidance
    In development

  6. Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]

    In development Reference number: GID-TA11230 Expected publication date:  22 April 2026

    Technology appraisal guidance
    In development

  7. Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]

    In development Reference number: GID-TA10223 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]

    Awaiting development Reference number: GID-TA10774 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Ibrutinib for untreated mantle cell lymphoma [ID1221]

    Discontinued Reference number: GID-TA10185

    Technology appraisal guidance
    Discontinued

  10. Venetoclax for treating chronic lymphocytic leukaemia (TA796)

    Evidence-based recommendations on venetoclax (Venclyxto) for chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    15 June 2022
    View recommendations

    Sections for TA796

  11. Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

    Discontinued Reference number: GID-TA10722

    Technology appraisal guidance
    Discontinued

  12. Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]

    Discontinued Reference number: GID-TA10447

    Technology appraisal guidance
    Discontinued

  13. Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270

    Discontinued Reference number: GID-TA10211

    Technology appraisal guidance
    Discontinued

  14. Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma [ID997]

    Discontinued Reference number: GID-TA10382

    Technology appraisal guidance
    Discontinued

  15. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID977]

    Discontinued Reference number: GID-TA11238

    Technology appraisal guidance
    Discontinued